The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Nice summary franksel thankyou,
Would just add a couple of minor points:
1. I understood the framework agreement was slightly higher with a potential value of £10 - 15m pa over the 10 yr period.
2. With the 3 manufacturing sites in the usa and with their previously stated involvement in diagnostic testing components over there, I would hope they are currently in a rich seam of work, given the news re testing in the USA and their preferance for domestic made products.
3. The recent capacity expansion progress at Mitcham (uk), USA, Europe & India (+all working 24/7) + managements bullish statements regarding beating expectations this year, both short & long term prospects are looking good.
First time I have seen this (old) clip of the Medusa19 assembly line in the uk. Thanks to Magnet 30 on abingdon wall for the link.
Cancel Christmas, double time for the employees, keep the belts running 24/7 !
Avacta's affimers in each one + profit share on distribution, win- win.
GLA
https://alderleyanalytical.com/good-luck-medusa-19/
Great news this morning that Avacta via meduflow (Medusa 19) have received aproval to sell direct for home use.
Carclo's previously discussed links with Avacta may help to explain yesterdays price rise.
EU & UK markets now open ( +Joe Biden's 500 m adding to the demand) hopefully we will be running the newly installed unit at Mitcham 24/7 for this one (+ others).
Anyway GLA
https://www.londonstockexchange.com/news-article/AVCT/affidx-receives-ce-mark-for-consumer-self-testing/15260813
Affimers winning again. Well done Amy Turner, we’ll worth a view of her “Death Star” video
RSC Chemical Biology and Bioorganic Group
@RSC_CBBG
·
3h
Congrats to poster award winners
@ChemicalScience
Award: Amy Turner @AmyTurner67763683
@UniversityLeeds
Oncology Tube
@oncologytube
New treatment approach targets cancer 'Death Star' Amy Turner, PhD
@AmyTurn67763683
@Tomlinson_lab
@AstburyCentre
@ScienceLeeds
#RAS #RASprotein #Affime #Cancer #Research
https://oncologytube.com/video/40048/amy-turner-phd-amyturn67763683-tomlinson_lab-astburycentre-scienceleeds-ras-rasprotein-affime-cancer-research-new-treatment-approach-targets-cancer-death-star?channelName=cancernewsupdate…
Not sure if this has been posted before or if it involves Avacta, but the timing with the recent RNS looks good.
LG Chem initiates clinical development of next-generation new drugs for treatment of arthritis
https://www.lgchem.com/company/information-center/press-release/news-detail-8788?lang=en_GLOBAL
Ref 8 th Feb RNS
"The longer-term collaboration with Mologic, on a range of diagnostic tests, offers a significant potential opportunity for the Group."
Reading this, I feel that Avacta won't to far away from this research & development initiative in improving lateral flow test performance.
https://www.bioaster.org/event/bioaster-awarded-grant-for-the-development-of-a-new-multiplex-technology-adapted-to-point-of-care-diagnosis/
Good to see that LG chem LS view us as one of their major partners, enough to be on their global map!
So it is not just us doing the shouting about the deal.
Looking forward to further anouncements on this front.
Partnershttps://innovation.lgchem.com/ResearchDevelopment/Partnership.do
As a useful aside, the ING +data so far, should be enough to trigger the remainder of the initial milestone payment from Point, of $750k (% $1m, $250k previously received).
This in addition to the LG significant milestone trigger reached a couple of months ago, should help towards the cash position.
Transformative times, GLA
Today's RNS and the positive data to date, may give confidence to Point for them to press on with their development work. As they stated they were awaiting data from this trial.
From Points IPO doc.
”Preclinical Data and Next Steps. (p92)
We are currently evaluating development plans to advance our tumor microenvironment targeting technology prodrug platform, and plan to assess its application to PMSA targeting ligands. Avacta Life Sciences has recently received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for its Clinical Trial Authorisation (CTA) in the UK for a Phase 1 study of its lead pre | CISIONTM prodrug, AVA6000 pro-doxorubicin, and we eagerly await the clinical data from their program as well as it may help us inform our own development plans"
Further details of Point’s plans again from the ipo doc, they may be seeing some early data from ava6000 ( ref the last sentence).
Our solution: Tumor Microenvironment Targeting Technology
We began investigating technologies which could be used to increase the therapeutic index of radiopharmaceuticals due to our interest in the future of radioligand therapies that will be used earlier in the treatment setting with a wider variety of radioisotopes. These investigations lead to the work of Dr. William Bachovchin of Tufts University / Bach Biosciences, which had previously invented a prodrug technology to increase the therapeutic index of chemotherapy drugs like doxorubicin. Dr. Bachovchin’s technology had been licensed to a UK-based life sciences firm named Avacta Life Sciences, who subsequently branded the technology as pre | CISION™. We have secured a sub-licensing agreement with Bach Biosciences and Avacta that provides us the right to apply the technology to radiopharmaceuticals globally.
Our tumor microenvironment targeting technology could decrease the risks associated with off-target delivery of radiopharmaceuticals by limiting their ability to bind with receptors on healthy cells. The way our tumor microenvironment targeting technology achieves this is by using the presence of fibroblast-activation proteins, which is expressed in over 90% of epithelial cancers but not expressed in healthy cells, as a switch that activates the radioligand. The following image visually explains how our tumor microenvironment targeting technology works:
[MISSING IMAGE: TM2123357D1-ORG_DRUG4CLR.JPG]
Our tumor microenvironment targeting technology is first conjugated with the radioligand, which effectively blocks the radioligand from bonding with receptors. The presence of FAP-a in the tumor microenvironment then cleaves our tumor microenvironment targeting technology off the radioligand. Once our tumor microenvironment targeting technology is removed, the radioligand can once again bind to cancer cell receptors. If the radioligand does not encounter a cancer cell, our tumor microenvironment targeting technology remains conjugated to it and is eliminated from the body without accumulating in off-target tissues expressing the receptor.
Preclinical Data and Next Steps
We are currently evaluating development plans to advance our tumor microenvironment targeting technology prodrug platform, and plan to assess its application to PMSA targeting ligands. Avacta Life Sciences has recently received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for its Clinical Trial Authorisation (CTA) in the UK for a Phase 1 study of its lead pre | CISIONTM prodrug, AVA6000 pro-doxorubicin, and we eagerly await the clinical data from their program as well as it may help us inform our own development plans.
From point ipo doc more details of the agreement
License agreement with Avacta Lifesciences Limited (“AVACTA”) for Tumor Microenvironment Targeting Technology
In December 2020, we entered into an agreement with AVACTA (“AVACTA Agreement”). Under the AVACTA Agreement, we became a sublicensee of AVACTA’s license for using the intellectual property of developing and marketing radiopharmaceutical agents. Under this agreement, we obtained an exclusive license of AVACTA’s patent rights to use, develop, manufacture and commercialize any FAP-activated PSMA targeted radiopharmaceutical and a non-exclusive license of AVACTA’s patent rights for other FAP-activated radiopharmaceuticals arising from the licensed technology.
We will pay during 2021 an upfront payment of $1.0 million for the initial license fee, $250,000 of which has already been paid and the remaining payments are due upon preclinical milestones. We are further obligated to make aggregate milestone payments to AVACTA of up to $4,500,000, upon the achievement of specified development milestones for our first product and up to $3,000,000 each for any license products upon reaching the specified development milestone. In addition, we are obligated to pay a milestone payment of $5,000,000 for each product for the regulatory milestone of being approved in specified territories. There is also an additional single digit percentage fee payable to AVACTA for monetary payments arising from a grant of a sublicense to a sublicensee or in the form of other benefits. We are also obligated to pay a single digit percentage royalty (subject to a reduction on certain conditions) related to the annual net sales by us, our affiliates or our sublicensees for each licensed product or license process and a single digit percentage royalty on a specified product arising out of the patents. The royalty rate will be reduced by 50% for net sales occurring in the United States if there is no valid claim at the time of sale. There is also an additional single digit percentage fee payable to AVACTA for monetary payments arising from a grant of a sublicense to a sublicensee or in the form of other benefits. We are responsible for all costs and expenses incurred related to the development, manufacture, regulatory approval and commercialization of all licensed products. In January 2021, we paid $250,000 of the initial license fee.
98
TABLE OF CONTENTS
We have the right to terminate the AVACTA Agreement, subject to a prior notice of 90 days to AVACTA. If we fail or AVACTA fails to comply with any of its obligations or otherwise breaches the agreement, the other party may terminate the agreement. The AVACTA Agreement will expire on a Licensed Product-by-Licensed Product or Licensed Process-by-Licensed Process and country-by-country basis, upon the expiration of the Royalty Term in such country. The royalty term will expire on a licensed product-by-licensed product or licensed process-by-licensed process and countr
https://www.investormeetcompany.com/carclo-plc/register-investor
Interim results investor presentation + q&a.
12.30 today - may be worth a view!
I like the volume of tooling work, alot of it will have been done last year but only recognised this period - also chance to secure better (healthy) rates for the manufacturing follow-on contracts.
Looks good for the future, turnover & margin.
Good to see a big "WE'RE GROWING" sign at the front of Carclo's factory in Latrobe PA.
They are after additional staff - production possitions.
Ref Carclo Technical Plastics PA facebook page.
Looks like Carclo produce the Zedscan device & consumables, for cervical cancer screening. It's getting some good press coverage and traction in the market, as can been seen below.
Good that they are involved in such an important healthcare issue and growth diagnostic area.
GLA
"Colposcopy Market worth over $250mn by 2027
Published Date: August 31, 2021 Authors: Sumant Ugalmugle, Rupali Swain
Colposcopy Market size is set to surpass USD 250 million by 2027, according to a new research report by Global Market Insights Inc.
Market growth is attributed to the advancement in treatment and procedures, novel product launches as well as growing demand for disease diagnosis. For instance, Zedscan, a diagnostic system that is used alongside colposcopy to provide an objective assessment of the cervical epithelial tissue in real time. Also, it is a new adjunct which uses electrical impedance to help the colposcopist. The possible benefits include reduced need for biopsy as well as more efficient management of women with high grade disease."
Not sure if this has been discussed:
Sona's saliva test has been redesigned and ready to go back to the FDA. (allbeit with only average results)
Wonder if we are still looking at our spit test?
GLA
Hi Franksel,
Thanks for your assesment, its good to have multiple view points.
In addition with the main directors buying more shares at the end of june (@52p), 3 months into this period, when they would have good visability as to orders world-wide & potential margins for 2021/2, all adds to the upside strength.
As to the day to day share movements - no idea!!!
GLA
It will be interesting to see the outputs from various locations in the interims.
India with their new covid diagnoistic clean rooms coming on line in the spring and with the closures at the plant last year due to goverment Covid policy, now working flat out, we should see a big swing there in turnover.
They had been commited to one client but looked to diversify last year. Plenty of major global players expanding in india in the last 12 months.
From the business development managers linkedin.
Thangadurai Arunachalam
Business Development Manager at Carclo Technical Plastics Ltd
5mo
Carclo Technical Plastics added additional cleanroom capabilities at Bangalore facility, to support our Medical and Diagnostic customers in this Covid pandemic scale up requirements.
For more details contact us at a.thangadurai@carclo-plc.com
#medicaldevices #covid19pandemic #diagnostics #antigentesting #contractmanufacturing #iso13485 #cleanroom #testkits #plasticinjectionmolding #medicaldevicemanufacturing #covid19india #carclo #diagnostictesting #oemsupplier
Thanks for posting. An interesting and enlightening read.